BMP-8A Lentiviral Activation Particles (h): sc-406589-LAC

BMP8A encodes bone morphogenetic protein 8A (BMP-8A), a secreted TGF-β superfamily ligand that signals through type I/II BMP receptors to activate SMAD1/5/9-dependent transcriptional programs. BMP-8A contributes to developmental patterning and tissue homeostasis by regulating cell fate decisions, differentiation, and morphogenetic processes, with downstream crosstalk to MAPK pathways that can refine context-specific responses. Altered BMP pathway activity, including dysregulated ligand availability or receptor-SMAD signaling, is broadly linked to defects in organogenesis and to disease-relevant changes in proliferation, differentiation, and extracellular matrix remodeling. As a human BMP ligand, BMP-8A is therefore a useful node for dissecting BMP/TGF-β signaling dynamics in stem cell biology and developmental models.

BMP-8A Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient BMP8A upregulation across a broader range of human cell types.

BMP-8A Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the BMP8A transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous BMP-8A expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native BMP8A genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.